Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

283
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
283
Microbiome of the Eye01:22

Microbiome of the Eye

67
The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
67

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sleep deprivation disrupts lacrimal gland homeostasis via hypothalamic-pituitary-adrenal axis and gut dysbiosis in mice.

Communications biology·2026
Same author

β-Adrenergic Signaling Contributes to Circadian and Lipid Dysregulation in Meibomian Glands During Chronic Psychological Stress.

Investigative ophthalmology & visual science·2026
Same author

Stress-Induced Disruption of Circadian and Neuroimmune Networks in Lacrimal Glands Drives Dry Eye Pathogenesis.

Investigative ophthalmology & visual science·2025
Same author

Photoexcitation Energy Transfer Patterning of 2D Materials with DNA Origami.

Small methods·2025
Same author

Breach and restoration of retinal immune privilege: barrier failure, innate dysregulation, and adaptive autoimmunity.

Frontiers in immunology·2025
Same author

Predictive value of miR-21 and miR-486 in clock-guided minimally invasive surgery for pulmonary nodules.

Biomarkers in medicine·2025

Related Experiment Video

Updated: May 3, 2026

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

14.9K

Multidimensional immunotherapy for dry eye disease: current status and future directions.

Duliurui Huang1,2, Zhijie Li1,2

  • 1Department of Ophthalmology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China.

Frontiers in Ophthalmology
|November 18, 2024
PubMed
Summary

Emerging immunotherapies offer new hope for Dry Eye Disease (DED) by targeting immune dysregulation and promoting ocular surface repair. Research explores novel treatments like biologics, gene therapy, and microbiome modulation for DED management.

Keywords:
Dry Eye Diseasegene therapyimmunotherapynanotechnologystem cell therapy

More Related Videos

Author Spotlight: Challenges in Developing Dry Eye Animal Models and Future Research Directions
04:06

Author Spotlight: Challenges in Developing Dry Eye Animal Models and Future Research Directions

Published on: February 9, 2024

1.8K
Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
05:21

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

465

Related Experiment Videos

Last Updated: May 3, 2026

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

14.9K
Author Spotlight: Challenges in Developing Dry Eye Animal Models and Future Research Directions
04:06

Author Spotlight: Challenges in Developing Dry Eye Animal Models and Future Research Directions

Published on: February 9, 2024

1.8K
Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
05:21

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

465

Area of Science:

  • Ophthalmology
  • Immunology
  • Regenerative Medicine

Background:

  • Dry Eye Disease (DED) is a complex condition involving tear hyperosmolarity and immune system dysfunction.
  • The immune system's role in DED pathogenesis contributes to inflammation and ocular surface damage.
  • Current treatments like anti-inflammatories have limitations due to side effects with long-term use.

Purpose of the Study:

  • To review emerging immunotherapies for Dry Eye Disease (DED).
  • To explore novel treatment modalities including biologics, stem cell therapy, gene therapy, nanotechnology, and exosome-based treatments.
  • To examine the role of the ocular microbiome and personalized immunotherapy in DED.

Main Methods:

  • Literature review of recent advancements in DED immunotherapy.
  • Analysis of emerging therapeutic strategies targeting immune pathways.
  • Exploration of the interplay between the ocular microbiome and DED.

Main Results:

  • Emerging immunotherapies show promise in modulating immune responses and enhancing tissue repair in DED.
  • Biologics, stem cell therapy, gene therapy, nanotechnology, and exosomes represent innovative treatment avenues.
  • The ocular microbiome's influence on DED pathogenesis is increasingly recognized, paving the way for personalized approaches.

Conclusions:

  • Novel immunotherapies offer potential for more effective and targeted DED treatment.
  • Further research is needed to optimize clinical translation and assess long-term efficacy.
  • Personalized immunotherapy, considering the ocular microbiome, may revolutionize DED management.